Maitalon (Drospirenone, Ethinylestradiol)

Maitalon, a combined oral contraceptive, is used to manage reproductive health by influencing hormonal regulation.

• Contraception: provides reliable prevention of unintended pregnancy in women of childbearing potential.
• Regulation of menstrual cycles: helps establish predictable menstrual bleeding patterns.
• Treatment of dysmenorrhea: reduces menstrual pain and associated symptoms.

• Drospirenone and ethinylestradiol act together to suppress the hypothalamic‑pituitary‑gonadal axis, lowering luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) release, which prevents ovulation. The estrogen component stabilises the endometrial lining, while the progestin component thickens cervical mucus and alters endometrial receptivity, thereby inhibiting fertilisation and implantation.

Maitalon may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: occasional stomach upset, especially when treatment is initiated.
• Headache: mild to moderate tension‑type headaches.
• Breast tenderness: temporary swelling or discomfort of the breasts.
• Spotting between periods: irregular light bleeding.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins, potentially life‑threatening.
• Stroke: rare cerebrovascular event, more likely in high‑risk individuals.
• Severe hypertension: significant rise in blood pressure requiring medical attention.

Before prescribing Maitalon, clinicians should consider several safety factors.

• Assess cardiovascular risk: evaluate history of thrombosis, smoking, hypertension, or obesity.
• Contraindicated in pregnancy: avoid use because of teratogenic risk (Category X).
• Monitor blood pressure: oral contraceptives may increase systolic and diastolic values.
• Review concomitant medications: enzyme‑inducing drugs can reduce effectiveness.
• Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Maitalon can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may markedly reduce contraceptive effect.
• Antifungal azoles (e.g., ketoconazole, itraconazole): can increase hormone levels, raising risk of side effects.
• Rifampin and other strong inducers: may significantly decrease effectiveness.

Moderate Interactions (Monitor Closely)

• Broad‑spectrum antibiotics (e.g., tetracycline, metronidazole): possible modest reduction in absorption.
• St. John’s wort: may lower plasma hormone concentrations.
• Diuretics: can affect fluid balance and blood pressure, requiring observation.